"The Foundation for Sickle Cell Disease Research (FSCDR) is committed to supporting innovative research in sickle cell disease to help maximize quality of life and improve survival for the generations of people affected with this disease. FSCDR is a comprehensive, non-profit organization that provides a platform for researchers, healthcare providers, individuals and their families living with sickle cell disease and supporters to work collaboratively in identifying barriers that are limiting creation, adoption and adherence to evidence-based screening recommendations, new therapeutics and best practices that help in the management of sickle cell disease."

During the past decade, Foundation for Sickle Cell Disease Research conducted 10 clinical trials. In the 10-year time frame, 10 clinical trials started and 2 clinical trials were completed, i.e. on average, 20% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 2 clinical trials were completed. i.e. 40% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Foundation for Sickle Cell Disease Research" #1 sponsor was "Imara, Inc." with 2 trials, followed by "Novartis Pharmaceuticals" with 2 trials sponsored, "Axcella Health, Inc" with 1 trials sponsored, "Cyclerion Therapeutics" with 1 trials sponsored and "Emory University" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Foundation for Sickle Cell Disease Research" #1 collaborator was "National Heart, Lung, and Blood Institute (NHLBI)" with 2 trials as a collaborator, "Blood and Marrow Transplant Clinical Trials Network" with 1 trials as a collaborator, "Dana-Farber Cancer Institute" with 1 trials as a collaborator, "Emory University" with 1 trials as a collaborator and "National Marrow Donor Program" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Foundation for Sickle Cell Disease Research" are "Sickle Cell Disease" (7 trials), "Anemia, Sickle Cell" (2 trials), "Breast Cancer" (1 trials), "Priapism" (1 trials) and "Sickle Cell Anemia" (1 trials). Many other conditions were trialed in "Foundation for Sickle Cell Disease Research" in a lesser frequency.

Most popular intervention types in "Foundation for Sickle Cell Disease Research" are "Drug" (7 trials), "Procedure" (2 trials), "Dietary Supplement" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "IMR-687" (2 trials), "Placebo" (2 trials), "AXA4010" (1 trials), "Alemtuzumab" (1 trials) and "Blood draw" (1 trials). Other intervention names were less common.

The vast majority of trials in "Foundation for Sickle Cell Disease Research" are 9 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Foundation for Sickle Cell Disease Research". undefined are not yet recruiting, 4 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Foundation for Sickle Cell Disease Research, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Foundation for Sickle Cell Disease Research, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".